Your browser doesn't support javascript.
loading
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
Shimazu, Yutaka; Murata, Makoto; Kondo, Takeshi; Minami, Yosuke; Tachibana, Takayoshi; Doki, Noriko; Uchida, Naoyuki; Ozawa, Yukiyasu; Yano, Shingo; Fukuda, Takahiro; Kato, Jun; Ara, Takahide; Eto, Testuya; Ishikawa, Jun; Nakamae, Hirohisa; Tanaka, Junji; Ichinohe, Tatsuo; Atsuta, Yoshiko; Nagamura-Inoue, Tokiko.
  • Shimazu Y; Department of Hematology, Kyoto University Hospital, Kyoto, Japan.
  • Murata M; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Kondo T; Department of Hematology, Aiiku Hospital, Sapporo, Hokkaido, Japan.
  • Minami Y; Department of Hematology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Tachibana T; Department of Hematology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
  • Doki N; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Uchida N; Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations TORANOMON, Tokyo, Japan.
  • Ozawa Y; Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Aichi, Japan.
  • Yano S; Department of Internal Medicine, Division of Clinical Oncology and Hematology, the Jikei University School of Medicine, Tokyo, Japan.
  • Fukuda T; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Kato J; Department of Medicine, Division of Hematology, Keio University School of Medicine, Tokyo, Japan.
  • Ara T; Department of Hematology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
  • Eto T; Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
  • Ishikawa J; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.
  • Nakamae H; Department of Hematology, Osaka City University Hospital, Osaka, Japan.
  • Tanaka J; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
  • Ichinohe T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Aichi, Japan.
  • Nagamura-Inoue T; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagoya, Aichi, Japan.
Hematol Oncol ; 40(3): 442-456, 2022 Aug.
Article en En | MEDLINE | ID: mdl-35394658
ABSTRACT
The introduction of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) treatment has dramatically improved the prognosis of CML patients and reduced the number of patients receiving allogeneic stem cell transplantation (allo-SCT). However, the impact of the newest-generation TKIs on the overall survival (OS) after allo-SCT has not been well described. To investigate the beneficial effects of TKIs on the prognosis after allo-SCT, we conducted a retrospective observational study using the Transplant Registry Unified Management Program database in Japan. We analyzed 1188 patients (male/female 738/450; median age 44 years; range 16-75) who underwent their first allo-SCT between January 2001 and December 2018. We divided the patients into two groups according to the TKI treatment used before allo-SCT group 1 was treated with the first generation TKI imatinib; group 2 was treated with the second generation TKIs nilotinib, dasatinib, or bosutinib and/or the third generation TKI ponatinib. We compared the post allo-SCT OS between the two groups. The 3-year OS rates (95%CI) of groups 1 and 2 were 59.3% (54.8%-63.5%) and 65.8% (61.6%-69.6%), respectively (p = 0.017). Multivariate analysis confirmed that group 2 had superior OS after allo-SCT compared to group 1 (p = 0.002). Other factors associated with superior prognosis were age ≤65, performance status (PS) 0/1, a 6/6 HLA-matched donor and chronic-phase (CP) disease status at allo-SCT. A subgroup analysis showed poor prognoses for patients who could not obtain a molecular response before allo-SCT and patients with positive T315I mutation in the BCR/ABL gene. In group 2, early allo-SCT was correlated with superior OS in patients with a blast-crisis disease status at allo-SCT (p = 0.001). The cumulative incidence of non-relapse mortality rate significantly decreased in group 2 (p = 0.0005). The post allo-SCT OS was improved both by pre- and post-management of allo-SCT and by the introduction of newer TKIs.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article